Fish oil study
This article was originally published in The Tan Sheet
Fish oil supplements did not protect against irregular heartbeats for patients with implantable cardioverter-defibrillators (ICDs), according to a study published in the Journal of the American Medical Association June 14. The year-long study involved 546 patients with ICDs and prior documented incidences of ventricular tachycardia (VT) or ventricular fibrillation (VF) who received either two grams of fish oil per day, or placebo. Trial endpoints were appropriate ICD intervention for VT or VF, or all-cause mortality. In the fish oil group, 27% required ICD intervention for VT or VF versus 30% in the placebo group. "In contrast to other...[studies], we did not find that fish oil may have proarrhythmic properties," Ingeborg Brouwer, PHD, Wageningen University, the Netherlands, et al., state...
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.